Peanut Allergy Treatment Market Size - Global Industry, Share, Analysis, Trends and Forecast 2023 - 2032
The Peanut Allergy Treatment Market Size accounted for USD 437 Million in 2022 and is projected to achieve a market size of USD 1,273 Million by 2032 growing at a CAGR of 11.5% from 2023 to 2032.
Peanut Allergy Treatment Market Highlights
- Global peanut allergy treatment market revenue is expected to increase by USD 1,273 million by 2032, with a 11.5% CAGR from 2023 to 2032
- North America region led with more than 40% of peanut allergy treatment market share in 2022
- Peanut allergy (PA) affects about 2% of the general population in Western countries and may be growing in incidence.
- Asia-Pacific peanut allergy treatment market growth will record a CAGR of more than 12.3% from 2023 to 2032
- By drug class, the epinephrine segment captured more than 47% of revenue share in 2022.
- By distribution channel, the retail pharmacy segment is projected to expand at the fastest CAGR over the projected period
- Growing awareness and diagnosis of peanut allergies, drives the peanut allergy treatment market value
Peanut allergy (PA) stands out from other food allergies due to its higher prevalence of accidental exposure, severe responses, and potentially lethal anaphylaxis. Approximately 7%-14% of PA patients experience accidental peanut exposure each year, with one-third to one-half potentially facing anaphylaxis, although fatalities are rare. These risks result in significantly higher healthcare utilization and economic expenditures for people with PA, as well as limitations on their everyday activities.
Peanut allergy treatment has traditionally focused on allergen avoidance and emergency management of allergic reactions, given the absence of a widely accepted cure. However, recent years have seen promising developments in immunotherapy, an approach aimed at desensitizing individuals to allergens by gradually exposing them to increasing amounts. This process helps the immune system build tolerance over time. One notable example is the investigational oral immunotherapy drug AR101, which is being studied for its potential to reduce allergic reactions to peanuts.
As for market growth, the peanut allergy treatment market is expected to witness expansion due to the increasing prevalence of peanut allergies worldwide. Rising awareness of food allergies, advancements in research and development, and efforts to improve treatment options are driving factors for potential growth. Biopharmaceutical companies are actively investing in developing innovative therapies to address unmet medical needs in the field of food allergies, including peanuts. The market growth is also influenced by a growing demand for effective and safe treatment options, given the severe consequences of peanut allergies and the significant unmet need for therapies that could improve the quality of life for individuals with peanut allergies
Global Peanut Allergy Treatment Market Trends
Market Drivers
- Increasing prevalence of peanut allergies
- Growing awareness and diagnosis of peanut allergies
- Advancements in peanut allergy immunotherapy
- Supportive regulatory environment for allergy treatments
- Rising investment in research and development for innovative therapies
Market Restraints
- Concerns regarding the safety and long-term efficacy of peanut immunotherapy
- Limited accessibility to specialized allergy clinics
Market Opportunities
- Expansion of healthcare infrastructure for allergy diagnosis and treatment
- Integration of digital health solutions for personalized allergy management
Peanut Allergy Treatment Market Report Coverage
| Market | Peanut Allergy Treatment Market |
| Peanut Allergy Treatment Market Size 2022 | USD 437 Million |
| Peanut Allergy Treatment Market Forecast 2032 | USD 1,273 Million |
| Peanut Allergy Treatment Market CAGR During 2023 - 2032 | 11.5% |
| Peanut Allergy Treatment Market Analysis Period | 2020 - 2032 |
| Peanut Allergy Treatment Market Base Year |
2022 |
| Peanut Allergy Treatment Market Forecast Data | 2023 - 2032 |
| Segments Covered | By Drug Class, By Route Of Administration, By Distribution Channel, And By Geography |
| Regional Scope | North America, Europe, Asia Pacific, Latin America, and Middle East & Africa |
| Key Companies Profiled | Aimmune Therapeutics Inc., Sanofi, Aravax Pty Ltd, Regeneron Pharmaceuticals Inc., Alladapt Immunotherapeutics, Inc., DBV Technologies, Prota Therapeutics, Vedanta Biosciences, Inc., and Teva Pharmaceuticals Industries Ltd. |
| Report Coverage |
Market Trends, Drivers, Restraints, Competitive Analysis, Player Profiling, Covid-19 Analysis, Regulation Analysis |
Peanut Allergy Treatment Market Dynamics
Peanut allergy treatment primarily focuses on mitigating the risk of severe allergic reactions in individuals with hypersensitivity to peanuts. One notable approach is oral immunotherapy (OIT), which involves the controlled and gradual introduction of small, increasing doses of peanut protein to the allergic individual. This process aims to desensitize the immune system, helping the person tolerate peanuts and reduce the severity of allergic reactions over time. OIT is typically administered under the supervision of healthcare professionals, often allergists, and involves careful monitoring of the patient's response to ensure safety. The applications of peanut allergy treatment are centered around improving the quality of life for individuals with peanut allergies. By building tolerance through immunotherapy, patients may experience reduced anxiety about accidental exposure to peanuts and a decreased likelihood of severe allergic reactions.
The peanut allergy treatment market has been witnessing notable growth, driven by several factors. The increasing prevalence of peanut allergies, coupled with a growing awareness and diagnosis of these allergies, has significantly expanded the patient pool seeking effective treatments. Peanut allergy is one of the most common food allergies worldwide, notably in the Western world, where it affects around one in every 200 people in specific groups. Peanut allergy is predicted to affect 0.4% to 0.6% of the total UK population. According to research, peanut allergy accounts for around 28% of all food allergies in children, with half of these instances emerging before the child's first birthday. However, peanut allergy develops beyond the age of 15, accounting for just 7% of instances.
Advances in immunotherapy, particularly oral immunotherapy (OIT), have garnered attention as a promising avenue for desensitizing individuals to peanut allergens. This innovation has fueled research and development activities, attracting investments from pharmaceutical companies eager to address the unmet medical needs in this field. Despite the growth prospects, the peanut allergy treatment industry faces challenges and uncertainties. Safety concerns and questions about the long-term effectiveness of immunotherapy, coupled with the financial burden associated with these treatments, could potentially impede market growth.
Peanut Allergy Treatment Market Segmentation
The global Peanut Allergy Treatment Market segmentation is based on drug class, route of administration, distribution channel, and geography.
Peanut Allergy Treatment Market By Drug Class
- Antihistamines
- Immunotherapies
- Epinephrine
- Others
According to the peanut allergy treatment industry analysis, the epinephrine segment accounted for the largest market share in 2022. Epinephrine, administered through auto-injectors like EpiPen, acts quickly to alleviate the life-threatening symptoms of anaphylaxis, such as difficulty breathing, swelling, and a drop in blood pressure. The rising prevalence of peanut allergies has led to an increased demand for epinephrine auto-injectors, contributing to the growth of this segment. The growth of the epinephrine segment is also influenced by factors such as heightened awareness about the seriousness of peanut allergies, better education on anaphylaxis management, and initiatives promoting the availability and accessibility of epinephrine devices. Furthermore, regulatory measures and guidelines emphasizing the importance of having epinephrine readily available, especially in settings like schools and public spaces, have propelled the market for epinephrine auto-injectors.
Peanut Allergy Treatment Market By Route Of Administration
- Injectable
- Oral
- Others
In terms of route of administration, the injectable segment is expected to witness significant growth in the coming years. Injectable immunotherapy involves the administration of gradually increasing doses of peanut allergen extracts to build tolerance and reduce the severity of allergic reactions. This form of treatment aims to desensitize individuals to peanut allergens over time, offering a potential long-term solution beyond emergency interventions like epinephrine. The growth of the injectable segment can be attributed to advancements in peanut allergy immunotherapy research. Clinical trials and studies exploring the efficacy and safety of injectable immunotherapies have shown promising results, generating interest from both healthcare professionals and patients. The development of standardized allergen extracts and the refinement of dosing protocols contribute to the credibility and acceptance of injectable immunotherapy for peanut allergies.
Peanut Allergy Treatment Market By Distribution Channel
- Retail Pharmacy
- Hospital Pharmacy
- Others
According to the peanut allergy treatment market forecast, the retail pharmacy segment is expected to witness significant growth in the coming years. Retail pharmacies serve as convenient outlets for individuals with peanut allergies and their caregivers to obtain essential medications and emergency treatments, contributing to the overall expansion of the market. Moreover, the growth of the retail pharmacy segment is influenced by the rising awareness of peanut allergies and the importance of having immediate access to allergy management products. Pharmacies play a crucial role in educating patients about available treatments, proper medication usage, and the significance of adherence to prescribed regimens. With an increasing emphasis on patient-centric healthcare and self-management of allergies, the retail pharmacy segment is poised to continue its growth as a vital link between healthcare providers and individuals seeking peanut allergy treatments.
Peanut Allergy Treatment Market Regional Outlook
North America
- U.S.
- Canada
Europe
- U.K.
- Germany
- France
- Spain
- Rest of Europe
Asia-Pacific
- India
- Japan
- China
- Australia
- South Korea
- Rest of Asia-Pacific
Latin America
- Brazil
- Mexico
- Rest of Latin America
The Middle East & Africa
- South Africa
- GCC Countries
- Rest of the Middle East & Africa (ME&A)
Peanut Allergy Treatment Market Regional Analysis
North America is considered a dominating region in the peanut allergy treatment market due to several factors that contribute to its leadership in this industry. The region has witnessed a significant rise in the prevalence of peanut allergies, prompting heightened awareness and a proactive approach to addressing this public health concern. According to data published in The Journal of Allergy and Clinical Immunology, the prevalence of current self-reported peanut allergy (PA) among US adults is 2.9%, with 1.8% having compelling PA. Notably, more than 17% of persons with peanut allergies reported developing the disease as adults. Adults with childhood-onset PA reported physician-diagnosed PA at 75.4%, compared to 58.9% with adult-onset PA. Robust healthcare infrastructure, advanced research and development capabilities, and a high level of healthcare expenditure have positioned North America at the forefront of innovative peanut allergy treatments. Moreover, the regulatory environment in North America is conducive to the development and commercialization of allergy treatments, including those for peanut allergies. Regulatory agencies such as the U.S. Food and Drug Administration (FDA) play a crucial role in facilitating the approval and market entry of novel therapies. The presence of key pharmaceutical and biotechnology companies specializing in allergy treatments in North America further supports the region's dominance in the peanut allergy treatment market. Additionally, collaborations between research institutions, healthcare organizations, and industry players contribute to the continuous advancement of treatment options.
Peanut Allergy Treatment Market Player
Some of the top peanut allergy treatment market companies offered in the professional report include Aimmune Therapeutics Inc., Sanofi, Aravax Pty Ltd, Regeneron Pharmaceuticals Inc., Alladapt Immunotherapeutics, Inc., DBV Technologies, Prota Therapeutics, Vedanta Biosciences, Inc., and Teva Pharmaceuticals Industries Ltd.
Frequently Asked Questions
How big is the peanut allergy treatment market?
The peanut allergy treatment market size was USD 437 Million in 2022.
What is the CAGR of the global peanut allergy treatment market from 2023 to 2032?
The CAGR of peanut allergy treatment is 11.5% during the analysis period of 2023 to 2032.
Which are the key players in the peanut allergy treatment market?
The key players operating in the global market are including Aimmune Therapeutics Inc., Sanofi, Aravax Pty Ltd, Regeneron Pharmaceuticals Inc., Alladapt Immunotherapeutics, Inc., DBV Technologies, Prota Therapeutics, Vedanta Biosciences, Inc., and Teva Pharmaceuticals Industries Ltd.
Which region dominated the global peanut allergy treatment market share?
North America held the dominating position in peanut allergy treatment industry during the analysis period of 2023 to 2032.
Which region registered fastest CAGR from 2023 to 2032?
Asia-Pacific region exhibited fastest growing CAGR for market of peanut allergy treatment during the analysis period of 2023 to 2032.
What are the current trends and dynamics in the global peanut allergy treatment industry?
The current trends and dynamics in the peanut allergy treatment industry include increasing prevalence of peanut allergies, growing awareness and diagnosis of peanut allergies, and advancements in peanut allergy immunotherapy.
Which route of administration held the maximum share in 2022?
The injectable route of administration held the maximum share of the peanut allergy treatment industry.
Select Licence Type
Connect with our sales team
Why Acumen Research And Consulting
100%
Customer Satisfaction
24x7
Availability - we are always there when you need us
200+
Fortune 50 Companies trust Acumen Research and Consulting
80%
of our reports are exclusive and first in the industry
100%
more data and analysis
1000+
reports published till date
